South African regulators have won a court case against a pharmacy that produced its own versions of popular weight-loss injections. Despite this legal win, illegal and experimental drugs are still reportedly being sold openly, and new measures to curb the trade are not yet in force.

Both outlets describe a situation where enforcement is moving more slowly than the black-market supply. They point to the continuing challenge of shutting down sellers and the practical difficulty of protecting consumers while regulatory updates are still months away. The coverage also frames an information gap for the public, including how people may try to assess whether medicines sold outside official channels are safe.

While the reporting focuses on the same core events—court action, ongoing open sales, and delayed new rules—the emphasis differs. One outlet foregrounds the regulator’s capacity to keep pace with the market, while the other adds a more explicit consumer-oriented focus on recognising safer products and understanding why enforcement is lagging.